MedDay Secures €34 Million ($38.5M) New Funding

Biotin is an emerging therapy for the treatment of secondary progressive MS.

MedDay Secures €34 Million ($38.5M) New Funding

Postby ton » Fri Apr 08, 2016 8:58 am

Please visit this web:
http://www.medday-pharma.com/
User avatar
ton
Family Member
 
Posts: 72
Joined: Thu May 27, 2010 2:00 pm

Advertisement

Re: MedDay Secures €34 Million ($38.5M) New Funding

Postby CureOrBust » Fri Apr 08, 2016 3:34 pm

A direct link: http://www.medday-pharma.com/news-and-e ... w-funding/

Friday, April 08, 2016
MedDay Secures €34 Million ($38.5M) New Funding
Edmond de Rothschild Investment Partners led the Series B financing alongside existing investors Sofinnova Partners and InnoBio. Large Venture also participated in the operation.

Funds will drive a confirmatory phase 3 study in US to treat progressive multiple sclerosis with MedDay’s wholly-owned lead candidate, MD1003

Does anyone know if the following statement only relates to people who were in the original studies? or is there a method to access the MD100 (as opposed to sourcing your own Biotin)?
The drug is already commercialized in some European countries under “named patient use”.
User avatar
CureOrBust
Family Elder
 
Posts: 3341
Joined: Wed Jul 27, 2005 2:00 pm
Location: Sydney, Australia


Return to Biotin (Qizenday, Cerenday, MD1003)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service